Long-Term Maintenance of Optimal Treatment Targets for Skin and Itch Outcomes With Upadacitinib in Moderate-to-Severe Atopic Dermatitis: 140-Week Results From the Phase 3 Measure Up 1 and 2 Studies. (2024). SKIN The Journal of Cutaneous Medicine, 8(6), s449. https://doi.org/10.25251/skin.8.supp.449